AbbVie IncABBV
▲ PositiveTechnologyrelevance
EU approval of Boey, a novel botulinum neurotoxin serotype E, for frown lines
Impact on stocks 1
Biotech & Genomic Medicine
AbbVie IncThe European Commission has approved Allergan Aesthetics' Boey for the temporary improvement of moderate to severe glabellar lines in adults. Boey is the first and only botulinum neurotoxin serotype E approved in Europe, with clinical studies showing an onset of effect as early as eight hours after injection and results lasting two to three weeks. The treatment also received approval in Canada in June. Allergan Aesthetics is part of AbbVie, whose shares closed 4.21% higher at $254.39 on Thursday.
AbbVie IncEU approval of Boey, a novel botulinum neurotoxin serotype E, for frown lines